Halozyme Therapeutics to Present at Two Upcoming Investor Conference... ( SAN DIEGO March 7 2012 /- Haloz...)

Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March

Date:3/7/2012

SAN DIEGO, March 7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March:

24^th Annual Roth Conference in Dana Point on March 14, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.
Barclays Capital 2012 Global Healthcare Conference in Miami on March 14, 2012 at 4:15 p.m. ET/1:15 p.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentations will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and recordings will be made available for 90 days following the events. To access the live webcasts, please log on to Halozyme's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headqua
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
2. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
4. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
5. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
6. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
7. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
8. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
9. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
10. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
11. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)

Post Your Comments:

(Date:12/9/2013)... Cray Valley has introduced Krasol® LBH ... liquid polybutadiene additives. The mono-hydroxyl functional oligomer (monol) ... for reactive polybutadienes. The monol can also be ... 5000M). , As a long-chain alcohol (C250), the ... harsh environments, is hydrolytically stable, and is compatible ...

(Date:12/9/2013)... (Dec. 9, 2013) Carbon nanotubes carry plasmonic ... spectrum, but only if they,re metallic by nature ... Rice University laboratory of physicist Junichiro Kono disproved ... narrow-gap semiconducting nanotubes. , Knowing that metallic or ... frequencies opens up the possibility that the tubes ...

(Date:12/9/2013)... not difficult, but doing so efficiently and on a ... still rely on the electric grid and not a ... researchers from the University of Illinois at Urbana-Champaign and ... one step closer to tapping into the full potential ... create large sheets of nanotextured, silicon micro-cell arrays that ...

(Date:12/9/2013)... 9, 2013 Covagen today announced that the company has ... with an option to obtain an additional CHF 14 million ... to CHF 56 million. This is one of the largest ... Europe . This financing will mainly ... COVA322, the first clinical candidate generated using Covagen,s ...

Breaking Biology Technology:New Monol Oligomer Technology Expands Applications for Cray Valley’s Krasol Additives 2 Scientists scale terahertz peaks in nanotubes 2 Covagen Secures CHF 42 Million in Series B Financing 2 Covagen Secures CHF 42 Million in Series B Financing 3 Covagen Secures CHF 42 Million in Series B Financing 4

[0] New Monol Oligomer Technology Expands Applications for Cray Valley’s Krasol Additives [0] Scientists scale terahertz peaks in nanotubes [0] Research team finds way to make solar cells thin, efficient and flexible [0] Covagen Secures CHF 42 Million in Series B Financing

... Nov. 15, 2010 Celladon Corp., a biopharmaceutical ... innovative treatments for cardiovascular diseases, today announced that ... trial of MYDICAR® demonstrated significant improvements in clinical ... failure patients treated with the genetically-targeted enzyme replacement ...

... ... ... ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...

... Talecris Biotherapeutics (Nasdaq: TLCR ) announced today ... that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) significantly ... to Alpha(1)-antitrypsin (AAT) deficiency. Results of the studies, published ... two similar pilot trials, were published in the journal ...

Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo Elsevier Announces the SciVerse ScienceDirect eBooks Collection 2011 Frontlist Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema

(Date:12/8/2013)... laboratory mouse is an important model for addressing ... questions have become more refined, and mouse models ... cancer therapeutics. Thus, the need for more sophisticated ... has the need for innovative tools to analyze ... A Laboratory Manual from Cold Spring Harbor ...

(Date:12/8/2013)... a gene that drives the development of tumours in ... is the first time that the gene CUX1 has ... discovered that, when CUX1 is deactivated, a biological pathway ... the biological pathway are currently being used in the ... new targeted therapy for patients with this type of ...

(Date:12/8/2013)... According to Gertrude Stein, "A rose is a rose ... not be the case when it comes to the ... institutions have found that as much as 30 percent ... between any two individuals. This substantial variation is in ... odors. , Humans have about 400 different types ...

Breaking Biology News(10 mins):Gene promotes 1 in 100 of tumors 2 Extensive variability in olfactory receptors influences human odor perception 2

[0] New book on mouse models of cancer from Cold Spring Harbor Laboratory Press [0] Gene promotes 1 in 100 of tumors [0] Extensive variability in olfactory receptors influences human odor perception

... McMaster researchers have found one more reason to exercise: working ... fat, improving overall health by boosting the body,s capacity to ... likely to become fat or bone, depending on which path ... the Department of Kinesiology,s Gianni Parise has shown that aerobic ...

... 1, 2011The American Society for Cell Biology,s (ASCB) online library ... Choice Award for favorite website. The Scientist announced that ASCB,s ... Readers, Choice poll with 1,072 votes, beating out the runner ... on the heels of the ASCB image library,s first anniversary, ...

... 2011 Systech International®, the recognized global ... European system integrator and provider of innovative ... services, today announced their partnership. As part ... Service Provider (VAR/SSP)" program, Zetes will sell, ...

Cached Biology News:Exercise boosts health by influencing stem cells to become bone, not fat, McMaster researchers find 2 Systech International and Zetes Partner to Meet Europe's Emerging Pharmaceutical Regulatory Requirements 2 Systech International and Zetes Partner to Meet Europe's Emerging Pharmaceutical Regulatory Requirements 3

Exercise boosts health by influencing stem cells to become bone, not fat, McMaster researchers find ASCB's online image library wins 'Labby' Readers' Choice Website Award from the Scientist'Systech International and Zetes Partner to Meet Europe's Emerging Pharmaceutical Regulatory Requirements

Request Info...

R26.4C...

... Chicken polyclonal to Opsin 1 ( Abpromise ... Synthetic peptide: YEDSTHASIFTYT, corresponding to amino acids ... synthetic peptide corresponding to amino acids 18/30 of ... used as immunogen. Entrez Gene ...

Biology Products:

8 Channel Syringe Dispenser, 20 cc Capacity from Biosearch Technologies Anti-sm (Smith Antigen) (SLE / Nuclear Marker) Ab-1 Monoclonal Antibody, Unconjugated from Lab Vision Rat Anti-Mouse ZO-1 Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank Chicken Anti-Opsin 1 Polyclonal Antibody, Unconjugated from Abcam